Industry News (Joint Venture)

Agreement Signed To Develop and Market Viral Gene Therapy

Published in Gene Therapy Weekly, February 3rd, 1997

Alexion Pharmaceuticals, Inc., New Haven, Connecticut, and Genetic Therapy, Inc. (GTI), have entered into an agreement in which Alexion has granted to GTI exclusive worldwide rights to use Alexion's technology to develop and market immunoprotected viral gene therapy products for direct in vivo gene therapy.

"This exciting new technology will boost our efforts to overcome the technical difficulties related to the injectability of retroviral vectors, and further strengthen our lead in the development of true in vivo gene therapy," said Dr. Paul Herrling, Novartis Pharma Research. "Much of GTI's research focuses on targetable, injectable, regulatable vectors which are of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1997-02-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry